WO2010011161A1 - Procédé pour obtenir un vaccin cellulaire visant de prévention du cancer du sein - Google Patents
Procédé pour obtenir un vaccin cellulaire visant de prévention du cancer du sein Download PDFInfo
- Publication number
- WO2010011161A1 WO2010011161A1 PCT/RU2009/000368 RU2009000368W WO2010011161A1 WO 2010011161 A1 WO2010011161 A1 WO 2010011161A1 RU 2009000368 W RU2009000368 W RU 2009000368W WO 2010011161 A1 WO2010011161 A1 WO 2010011161A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- cells
- tumor
- mice
- bbcv
- gel
- Prior art date
Links
- 206010006187 Breast cancer Diseases 0.000 title claims abstract description 12
- 208000026310 Breast neoplasm Diseases 0.000 title claims abstract description 6
- 229940030156 cell vaccine Drugs 0.000 title claims description 5
- 238000004519 manufacturing process Methods 0.000 title abstract description 5
- 206010028980 Neoplasm Diseases 0.000 claims abstract description 32
- 239000002775 capsule Substances 0.000 claims abstract description 21
- 210000002808 connective tissue Anatomy 0.000 claims abstract description 13
- 238000002255 vaccination Methods 0.000 claims abstract description 11
- 210000004027 cell Anatomy 0.000 claims description 52
- 241000699670 Mus sp. Species 0.000 claims description 37
- 239000000499 gel Substances 0.000 claims description 15
- 238000000338 in vitro Methods 0.000 claims description 9
- 239000012980 RPMI-1640 medium Substances 0.000 claims description 7
- 238000004113 cell culture Methods 0.000 claims description 7
- 238000000034 method Methods 0.000 claims description 7
- 210000002966 serum Anatomy 0.000 claims description 7
- 230000001605 fetal effect Effects 0.000 claims description 6
- 102000004142 Trypsin Human genes 0.000 claims description 5
- 108090000631 Trypsin Proteins 0.000 claims description 5
- 239000012588 trypsin Substances 0.000 claims description 5
- 229920002401 polyacrylamide Polymers 0.000 claims description 4
- 230000002265 prevention Effects 0.000 claims description 4
- 239000002356 single layer Substances 0.000 claims description 4
- 241000283690 Bos taurus Species 0.000 claims description 3
- 239000006144 Dulbecco’s modified Eagle's medium Substances 0.000 claims description 3
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 claims description 3
- 210000002919 epithelial cell Anatomy 0.000 claims description 3
- 230000002269 spontaneous effect Effects 0.000 claims description 3
- 230000012010 growth Effects 0.000 claims description 2
- 239000007788 liquid Substances 0.000 claims description 2
- 210000005075 mammary gland Anatomy 0.000 claims description 2
- 229920001296 polysiloxane Polymers 0.000 claims description 2
- 239000011543 agarose gel Substances 0.000 claims 1
- 238000006116 polymerization reaction Methods 0.000 claims 1
- 231100000331 toxic Toxicity 0.000 claims 1
- 230000002588 toxic effect Effects 0.000 claims 1
- 241001465754 Metazoa Species 0.000 abstract description 15
- 229960005486 vaccine Drugs 0.000 abstract description 15
- 208000009956 adenocarcinoma Diseases 0.000 abstract description 12
- 201000010099 disease Diseases 0.000 abstract description 9
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract description 9
- 238000002360 preparation method Methods 0.000 abstract description 6
- 238000002054 transplantation Methods 0.000 abstract description 6
- 230000036039 immunity Effects 0.000 abstract description 5
- 230000000259 anti-tumor effect Effects 0.000 abstract description 3
- 230000002163 immunogen Effects 0.000 abstract description 3
- 239000000463 material Substances 0.000 abstract description 3
- 230000003449 preventive effect Effects 0.000 abstract description 3
- 210000001519 tissue Anatomy 0.000 abstract description 3
- 230000001575 pathological effect Effects 0.000 abstract description 2
- 238000002689 xenotransplantation Methods 0.000 abstract description 2
- 239000003795 chemical substances by application Substances 0.000 abstract 1
- 241000699666 Mus <mouse, genus> Species 0.000 description 15
- 241000282412 Homo Species 0.000 description 5
- 230000000735 allogeneic effect Effects 0.000 description 5
- 201000008274 breast adenocarcinoma Diseases 0.000 description 5
- 238000002474 experimental method Methods 0.000 description 5
- 238000007920 subcutaneous administration Methods 0.000 description 5
- 210000004881 tumor cell Anatomy 0.000 description 5
- 241000700647 Variola virus Species 0.000 description 4
- 241000700605 Viruses Species 0.000 description 4
- 230000000694 effects Effects 0.000 description 4
- 239000002609 medium Substances 0.000 description 4
- 230000001681 protective effect Effects 0.000 description 4
- 239000000243 solution Substances 0.000 description 4
- 229920000936 Agarose Polymers 0.000 description 3
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 3
- 238000005119 centrifugation Methods 0.000 description 3
- 238000011109 contamination Methods 0.000 description 3
- 210000004408 hybridoma Anatomy 0.000 description 3
- 210000000481 breast Anatomy 0.000 description 2
- 201000011510 cancer Diseases 0.000 description 2
- 239000012091 fetal bovine serum Substances 0.000 description 2
- 238000002347 injection Methods 0.000 description 2
- 239000007924 injection Substances 0.000 description 2
- 238000007912 intraperitoneal administration Methods 0.000 description 2
- 108010082117 matrigel Proteins 0.000 description 2
- 230000000771 oncological effect Effects 0.000 description 2
- 230000000069 prophylactic effect Effects 0.000 description 2
- 238000011321 prophylaxis Methods 0.000 description 2
- 229910052710 silicon Inorganic materials 0.000 description 2
- 239000010703 silicon Substances 0.000 description 2
- 238000010561 standard procedure Methods 0.000 description 2
- 230000005740 tumor formation Effects 0.000 description 2
- 230000004614 tumor growth Effects 0.000 description 2
- 208000031295 Animal disease Diseases 0.000 description 1
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 1
- 108091005904 Hemoglobin subunit beta Proteins 0.000 description 1
- 206010027476 Metastases Diseases 0.000 description 1
- 241000204031 Mycoplasma Species 0.000 description 1
- 208000037273 Pathologic Processes Diseases 0.000 description 1
- 108010015078 Pregnancy-Associated alpha 2-Macroglobulins Proteins 0.000 description 1
- 235000018259 Solanum vestissimum Nutrition 0.000 description 1
- 240000002825 Solanum vestissimum Species 0.000 description 1
- 108010017842 Telomerase Proteins 0.000 description 1
- 241000700618 Vaccinia virus Species 0.000 description 1
- 241000251539 Vertebrata <Metazoa> Species 0.000 description 1
- 208000035472 Zoonoses Diseases 0.000 description 1
- 230000035508 accumulation Effects 0.000 description 1
- 238000009825 accumulation Methods 0.000 description 1
- 238000011316 allogeneic transplantation Methods 0.000 description 1
- 239000003708 ampul Substances 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 230000000890 antigenic effect Effects 0.000 description 1
- 238000013459 approach Methods 0.000 description 1
- 230000001580 bacterial effect Effects 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 238000002619 cancer immunotherapy Methods 0.000 description 1
- 230000010261 cell growth Effects 0.000 description 1
- 201000003740 cowpox Diseases 0.000 description 1
- 230000002559 cytogenic effect Effects 0.000 description 1
- 230000000120 cytopathologic effect Effects 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 231100000676 disease causative agent Toxicity 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 239000000945 filler Substances 0.000 description 1
- 239000012595 freezing medium Substances 0.000 description 1
- 230000002538 fungal effect Effects 0.000 description 1
- 230000005847 immunogenicity Effects 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 208000015181 infectious disease Diseases 0.000 description 1
- 238000001990 intravenous administration Methods 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 230000009401 metastasis Effects 0.000 description 1
- 231100000252 nontoxic Toxicity 0.000 description 1
- 230000003000 nontoxic effect Effects 0.000 description 1
- 235000015097 nutrients Nutrition 0.000 description 1
- 230000009054 pathological process Effects 0.000 description 1
- 230000007170 pathology Effects 0.000 description 1
- 108020004418 ribosomal RNA Proteins 0.000 description 1
- 239000000021 stimulant Substances 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 238000011282 treatment Methods 0.000 description 1
- 206010048282 zoonosis Diseases 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0011—Cancer antigens
- A61K39/00119—Melanoma antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/515—Animal cells
- A61K2039/5152—Tumor cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/80—Vaccine for a specifically defined cancer
- A61K2039/812—Breast
Definitions
- a method of obtaining a live cell vaccine for the prevention of breast cancer is a method of obtaining a live cell vaccine for the prevention of breast cancer.
- the invention relates to immuno-oncology and is a method for producing a transplantable line of mouse tumor cells having the properties of a vaccine against mammary adenocarcinoma.
- the obtained cell line Being a benign tumor of Balb / c mice, the obtained cell line is intended for transplantation into syngeneic animals only if cells are introduced into a previously created connective tissue capsule.
- the cell line thus obtained called BBCV, can be proposed as a safe immunogenic preparation for the prevention of breast adenocarcinoma in women.
- the BBCV line was deposited in the Specialized Collection of Vertebrate Cell Cultures of the Russian Cell Culture Collection and is stored in the MNIIME Cell Culture Bank, see Appendix, BBCV Cell Line Passport).
- the basis of the invention is the well-known Jennerra vaccine, which causes a pathological process similar to the disease in a person, but limited by the injection site and creates immunity against an antigenically related pathological principle
- Immunoprophylaxis in oncology is currently developing in several directions. The most attractive for clinicians is the post-surgical prophylaxis of metastasis and generalization of the tumor process.
- the drugs used in this area are called vaccines, in the sense that they act as active specific stimulants of antitumor disease. In a sense, their effect should be more therapeutic than prophylactic, which is important distinguishes the majority of oncological vaccines being developed from the classic preventive vaccines successfully used in ektsionnoy pathology.
- Prevention of the disease by artificially reproducing a similar but benign process was the initial vaccination that Sir Edward Jenner introduced into medical practice more than 200 years ago. Vaccination of cowpox, vassipia, vassa - cow (la), according to Generr, she began to fight the human smallpox virus long before the word virus and the description of smallpox virus
- the result of the invention is the creation of an antitumor vaccine, the use of which is based on the principle of grafting a living patient material from an animal with a similar disease to a person.
- a vaccine is obtained, which is a transplantable line of mouse tumor cells with the properties of a vaccine against mammary adenocarcinoma.
- principles were used that reveal the possibility of accumulation of clonal cell lines, described, for example, in US 4003789, C12N5 / 06, 01/18/1977 / 2, 4 /, as well as principles confirming the possibility of using an inert gel to create a connective tissue capsule described in US 6 972194, A61K 9/00, December 6, 2005/3 /.
- the basis of the invention is the use of a benign tumor of Balb / c mice, a cell line that is transplanted during transplantation into syngeneic animals only if cells are introduced into a previously created connective tissue capsule. Moreover, since the cell line can be infinitely cultivated ip vitro in DMEM / RPMI-1640 nutrient medium with 10% fetal bovine serum, which makes it possible to accumulate production quantities of standard vaccine material.
- the BBCV line was obtained from a benign spontaneous mammary tumor of a mouse of the Balb / c line in the laboratory of hybridoma biotechnology MNIIME and was cultivated for 7 years in vitro and in vivo.
- BBCV cells were cultured in vitro for 20 passages, then 22 passages in vitro were passed on Balb / c mice and then cultivated in vitro 25 passages.
- the cultivation medium -DMEM / RPMI-1640 with 10% fetal serum The cultivation temperature was + 37 ° C. Cells were inoculated once a week, scattering 1: 3 - 1: 4.
- the monolayer was rinsed twice with EDTA solution and 0.25% trypsin solution was removed in 2-3 minutes at room temperature.
- a biocompatible gel Microgel, Silicon, Agarose, and Polyacrylamide gel
- the encapsulated tumor was aseptically removed and trypsinized according to the standard procedure for the preparation of primary epithelial cell cultures: 2.5% trypsin, 20 min, 37 ° C. Trypsinization was stopped by the addition of 10% fetal serum k.p.c. Cells were besieged by centrifugation at 1500 rpm, resuspended in RPMI-1640 medium to a concentration of 1 million / ml and injected at a dose of 10 thousand - 1 million in a capsule formed by gel under the skin of mice of the Balb / s line. Tumor growth begins in 1 to 2 weeks.
- FIG. 1 summarizes the results of an experiment evaluating the vaccinating effect of BBCV cells for C57Black / 6 mice.
- Three groups of 4 mice were vaccinated by introducing cells into the connective tissue capsules formed under the skin in the scapular area by the preliminary injection of 0.5 ml of one of the following inert gels: 2% polyacrylamide, 2% agarose and liquid silicone (breast prosthesis filler), 4 animals per every gel.
- BBCV breast adenocarcinoma is a transplantable tumor that is syngenic for Balb / c mice provided that the tumor cells are transplanted into the connective tissue capsule and, as a result, it was concluded that the BBCV cell line can be used as a live allogeneic vaccine against mouse adenocarcinoma .
- mice with MCF-7 human adenocarcinoma The principal possibility of prophylactic vaccination in breast cancer with xenogenic tumor cells was shown by us in an experiment on vaccination of mice with MCF-7 human adenocarcinoma.
- MCF-7 cells grown under ip vitro conditions were injected into four G57Blac / 6 mice, with a junctional tissue capsule pre-formed under their skin. Cells were besieged by centrifugation and introduced into the capsule in a volume of 0.25 ml at a dose of 10 million cells per mouse. After 30 days, four control and four vaccinated mice under the skin were injected with 10 million cells of syngeneic adenocarcinoma Ca-755 (Fig. 3).
- the BBCV cell line can be proposed as a safe immunogenic preparation for the prophylaxis of breast adenocarcinoma in women.
- the implementation of the claimed method for producing a live cell vaccine provided the creation of a mouse cell line that does not cause tumor in syngeneic mice using conventional transplantation methods. Moreover, this mouse cell line transplanted as a benign tumor does not metastasize if syngeneic mouse is introduced into the connective tissue capsule.
- This line of mouse cells that induces protective immunity (vaccine) can be transplanted into a connective tissue capsule by allogeneic and xenogenic recipients.
- an allogeneic recipient is any mouse, not a Balb / c line, but a human being is an xenogenic solution.
- Cell Type Adenocarcinoma of the mammary gland of the mouse.
- the BBCV line was obtained from a spontaneous mammary tumor of a mouse of the Balb / c line in the laboratory of hybridoma biotechnology of MNIIME and was cultured for
- Timing causes a subcutaneous solid tumor when 10 thousand - 1.0 million cells are administered in a connective tissue capsule formed in Balb / s mice after administration of a non-toxic gel (Matrigel, Silicon, Agarose, PAAG). It does not cause tumors with subcutaneous, intraperitoneal and intravenous administration of 100 thousand cells to mice of the Balb / s, SZN, DBA.2 mice and
- RPMI-1640 to a concentration of 1 million / ml and injected in a dose of 10 thousand - 1 million in a capsule formed by polyacrylamide gel under the skin of mice of the line Balb / s. Tumor growth begins in 1 - 2 weeks and lasts for 1 -1.5 months.
- Cultivation of vit vit Cultivation medium - RPMI-1640 with 10% fetal serum The cultivation temperature is 37 ° C. Cells are inoculated once a week, scattering 1: 3 - 1: 4. The monolayer is rinsed twice with EDTA and removed with 0.25% trypsin solution for 2-3 MJJ at room temperature ..
- Morphology Polymorphic cells growing in a monolayer.
- Cytogenetics The mouse genotype is confirmed by PCR - analysis of beta globin genes, telomerase, and the properties of ribosomal RNA.
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Immunology (AREA)
- Epidemiology (AREA)
- Oncology (AREA)
- Mycology (AREA)
- Microbiology (AREA)
- Cell Biology (AREA)
- Organic Chemistry (AREA)
- Biomedical Technology (AREA)
- Engineering & Computer Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Biotechnology (AREA)
- Zoology (AREA)
- Developmental Biology & Embryology (AREA)
- Virology (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Abstract
La présente invention concerne la fabrication de produits pour prévenir le cancer du sein en utilisant une lignée cellulaire non métastasiante d’adénocarcinome murin en tant que préparation de prévention immunitaire se présentant comme un transplant de tumeur murine qui se développe pendant un temps limité dans une capsule en tissu conjonctif sous la peau humaine. L’invention vise à créer un vaccin antitumoral dont l’utilisation est basée sur le principe d’injection chez l’homme d’un matériau pathologique vivant provenant d’un animal souffrant d’une maladie similaire. Cette lignée cellulaire, qui se présente comme une tumeur bénigne des souris de la lignée Balb/c, se transplante chez des animaux syngéniques uniquement en cas d’introduction de cellules dans une capsule en tissu conjonctif préalablement créée. Lors d’une transplantation allogénique les cellules BBCV provoquent l’immunité protégeant les souris contre une dose suffisamment élevée de cellules d’adénocarcinome syngénique malin. Lors d’une xénotransplantation chez l’humain la lignée BBCV peut être proposée en tant que préparation immunogène sûre pour la prévention de l’adénocarcinome de la glande mammaire chez les femmes.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| RU2008130673 | 2008-07-25 | ||
| RU2008130673/13A RU2407789C2 (ru) | 2008-07-25 | 2008-07-25 | Способ получения живой клеточной вакцины для профилактики рака молочных желез |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| WO2010011161A1 true WO2010011161A1 (fr) | 2010-01-28 |
Family
ID=41570481
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PCT/RU2009/000368 WO2010011161A1 (fr) | 2008-07-25 | 2009-07-24 | Procédé pour obtenir un vaccin cellulaire visant de prévention du cancer du sein |
Country Status (2)
| Country | Link |
|---|---|
| RU (1) | RU2407789C2 (fr) |
| WO (1) | WO2010011161A1 (fr) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| RU2500392C2 (ru) * | 2011-11-16 | 2013-12-10 | Виктор Владимирович Кешелава | Способ профилактики онкологических заболеваний |
| RU2759487C1 (ru) * | 2021-04-22 | 2021-11-15 | федеральное государственное бюджетное учреждение «Национальный медицинский исследовательский центр онкологии» Министерства здравоохранения Российской Федерации | Способ усиления роста меланомы В16/F10 по сравнению с ростом меланомы В16/F10 при самостоятельной перевивке и замедления роста LLC (карциномы Льюиса) по сравнению с ростом LLC при самостоятельной перевивке при первично-множественных злокачественных опухолях на фоне первичного иммунодефицита |
Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6039941A (en) * | 1994-08-24 | 2000-03-21 | Max-Delbruck-Centrum Fur Molekulare Medizin | Live vaccine for the treatment of tumor diseases |
| US20030082136A1 (en) * | 2001-10-30 | 2003-05-01 | Bill Minshall | Anti-tumor vaccine |
| UA73671C2 (en) * | 2004-01-28 | 2005-08-15 | Kavetsky Inst Of Ex Pathology | Method for obtaining anticancer vaccine and method for treating cancer patients |
-
2008
- 2008-07-25 RU RU2008130673/13A patent/RU2407789C2/ru not_active IP Right Cessation
-
2009
- 2009-07-24 WO PCT/RU2009/000368 patent/WO2010011161A1/fr active Application Filing
Patent Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6039941A (en) * | 1994-08-24 | 2000-03-21 | Max-Delbruck-Centrum Fur Molekulare Medizin | Live vaccine for the treatment of tumor diseases |
| US20030082136A1 (en) * | 2001-10-30 | 2003-05-01 | Bill Minshall | Anti-tumor vaccine |
| UA73671C2 (en) * | 2004-01-28 | 2005-08-15 | Kavetsky Inst Of Ex Pathology | Method for obtaining anticancer vaccine and method for treating cancer patients |
Also Published As
| Publication number | Publication date |
|---|---|
| RU2407789C2 (ru) | 2010-12-27 |
| RU2008130673A (ru) | 2010-02-10 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ES2368981B1 (es) | Vacuna para la enfermedad producida por edwardsiella y la enfermedad producida por estreptococos en peces. | |
| ES2460899T3 (es) | Inmunoterapia basada en células cancerosas alógenas | |
| CN107708713B (zh) | 使用由减毒细菌递送的回忆抗原治疗癌症 | |
| DK1549353T3 (da) | Anvendelse af alfa(1,3)galactosyltransferaseudtrykkende allogene tumorceller til vaccination mod tumorer | |
| US8802113B2 (en) | Extracellular matrix cancer vaccine adjuvant | |
| AU2007309193B2 (en) | Extracellular matrix cancer vaccine adjuvant | |
| BR112013026661B1 (pt) | composição de vacina, usos da mesma e método para produzir a referida composição | |
| CN109078180A (zh) | 用于增强免疫响应的复合物 | |
| JP2018016651A (ja) | 能動免疫療法のためのＴｈ１ワクチン接種プライミング | |
| CA2233015A1 (fr) | Utilisation therapeutique de serums d'animaux, en particulier du cheval, pour le traitement du sida, du cancer et d'autres maladies virales et bacteriennes | |
| US8846059B2 (en) | Extracellular matrix adjuvant and methods for prevention and/or inhibition of ovarian tumors and ovarian cancer | |
| WO2010011161A1 (fr) | Procédé pour obtenir un vaccin cellulaire visant de prévention du cancer du sein | |
| KR20200142028A (ko) | 애주번트로서의 버크홀데리아 슈도말레이 복합체 외막 소포체 | |
| ES2335490T3 (es) | Vacunacion con celulas inmunoaisladas y productoras de un inmunomodulador. | |
| CN106267176B (zh) | 鸡传染性鼻炎疫苗组合物及其制备方法和应用 | |
| CN107384837A (zh) | 一株鸡滑液支原体及其应用 | |
| CN107137703B (zh) | 一种狂犬病免疫原性结合物和疫苗及其制备方法 | |
| Zhang et al. | Exosome co-delivery of a STING agonist augments immunogenicity elicited by CVB3 VP1 vaccine via promoting antigen cross-presentation of CD8+ DCs | |
| CN113117088B (zh) | 钙激活氯离子通道的抑制剂在肿瘤免疫疗法中的应用 | |
| RU2329828C1 (ru) | Способ изготовления вакцины для профилактики и лечения некробактериоза животных, вакцина для профилактики и лечения некробактериоза животных и способ профилактики и лечения некробактериоза животных | |
| JP6712760B2 (ja) | サルモネラワクチン | |
| CN107653231A (zh) | 鸭源性冠状病毒弱毒株ibvdcv35及其应用 | |
| Kajal et al. | From ancient remedies to modern miracles: tracing the evolution of vaccines and their impact on public health | |
| CN114401740A (zh) | 痘病毒与自体诱导性多能干细胞用于疫苗接种和疾病治疗的用途 | |
| Scott | Classifying vaccines |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| 121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 09800619 Country of ref document: EP Kind code of ref document: A1 |
|
| NENP | Non-entry into the national phase |
Ref country code: DE |
|
| 122 | Ep: pct application non-entry in european phase |
Ref document number: 09800619 Country of ref document: EP Kind code of ref document: A1 |